Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) (NCT04184050)
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people tolerate them. Researchers also want to learn what happens to different doses of MK-4002 in a person's body over time.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Mayo Clinic Arizona — Phoenix, Arizona
- UC San Diego Moores Cancer Center — La Jolla, California
- The University of Kansas Cancer Center — Fairway, Kansas
- Roswell Park Comprehensive Cancer Center — Buffalo, New York
- University of Rochester James P Wilmot Cancer Institute — Rochester, New York
- OHSU — Portland, Oregon
- University of Washington - Seattle Cancer Center Alliance — Seattle, Washington
- Centre Hospitalier Universitaire De Nantes — Nantes,
- Centre Hospitalier Universitaire de Poitiers — Poitiers,
- Josep Carreras Leukaemia Research Institute — Barcelona,
- Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) — Madrid,
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma in Relapse
- Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma — Denver, Colorado
- Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma — Fayetteville, Arkansas
- Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma — Aurora, Colorado
- A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma — West Hollywood, California
- A Trial of Selinexor, Ruxolitinib and Methylprednisolone — West Hollywood, California
Explore by condition: All Multiple Myeloma in Relapse clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.